Amarin (NASDAQ:AMRN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Amarin (NASDAQ:AMRN) in a research note issued to investors on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Amarin Price Performance

AMRN opened at $0.46 on Friday. Amarin has a 12 month low of $0.35 and a 12 month high of $1.11. The business has a 50-day moving average of $0.54 and a two-hundred day moving average of $0.54. The stock has a market capitalization of $188.50 million, a price-to-earnings ratio of -5.10 and a beta of 1.82.

Shares of Amarin are set to reverse split before the market opens on Friday, April 11th. The 1-20 reverse split was announced on Wednesday, March 12th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, April 10th.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $62.31 million for the quarter, compared to analyst estimates of $32.37 million. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. Equities research analysts anticipate that Amarin will post -0.15 earnings per share for the current year.

Institutional Investors Weigh In On Amarin

Institutional investors have recently added to or reduced their stakes in the company. Arkfeld Wealth Strategies L.L.C. lifted its stake in shares of Amarin by 52.6% in the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 20,000 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Amarin during the fourth quarter valued at approximately $36,000. Generation Capital Management LLC purchased a new stake in Amarin during the fourth quarter worth approximately $50,000. Stonepine Capital Management LLC purchased a new stake in Amarin during the fourth quarter worth approximately $55,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Amarin in the fourth quarter worth $68,000. Hedge funds and other institutional investors own 22.25% of the company’s stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.